Intel Corporation - INTC - Stock Price Today - Zacks Zacks Investment Research.
Since 2009, Dr. Rosenwald has served as Co-Portfolio Manager and Partner of Opus Point Partners, LLC ("Opus"), an asset management firm in the life sciences industry. Prior to that, from 1991 to 2008, he served as the Chairman of Paramount BioCapital , .
Synergy Pharmaceuticals logo Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Wednesday, September 13th. According to Zacks, “Synergy .
The company has successfully executed on its plan from day one under the outstanding leadership of Jon Vaught and Nick Hofmeister," said Micah Tapman, Managing Director at Canopy Boulder. "The cannabis industry raises a number of challenges for all.
teich andrew c - SEC.gov SEC.gov.
With me today on this call are several members of Sangamo's senior management , including Sandy Macrae, Chief Executive Officer; Ward Wolff, our Retiring Chief Financial Officer; Ed Conner, Chief Medical Officer; Michael Holmes, Vice President of .
Rockwell Automation logo TIAA CREF Investment Management LLC lowered its position in Rockwell Automation, Inc. (NYSE:ROK) by 6.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm .
He is currently employed as managing partner at View Partners, an investment bank based in New York City focused on merger and acquisition advisory for technology companies. He has 23 years of investment ..... My father is a professor of molecular.
Murphy Capital Management Inc. now owns 31,721 shares of the chip maker's stock worth $1,070,000 after buying an additional 4,928 shares during the last quarter. Sigma Planning Corp increased its position in Intel Corporation by 0.5% during the first.
This implies that Novavax can prove to be a much stronger investment opportunity in 2017. In this article, I plan to explain the key milestones that can catapult Novavax's share prices in 2017. Novavax has been rapidly enrolling subjects in its pivotal.
Paramount Group logo Paramount Group Inc (NASDAQ:PGRE) has been assigned a consensus recommendation of “Hold” from the eight analysts that are currently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a.
Sage Therapeutics, Inc. (NASDAQ:SAGE)'s stock had its “hold” rating reiterated by investment analysts at Chardan Capital in a report issued on Wednesday, September 13th. A number of other brokerages have also commented on SAGE. Canaccord ... holdings.
AbbVie is also involved in developing add-back therapies to manage bone mineral density in patients using Elagolix. ... In June 2010, Neurocrine Biosciences (NASDAQ:NBIX) entered into a partnership with the commercially stronger AbbVie (NYSE:ABBV) for.